Pharmaceutical-grade PVA with a 4% aqueous viscosity of 4.0–6.0 mPa·s at 20°C and a degree of hydrolysis of 87.0–89.0 mol% is charged into a high-shear granulator as a wet-granulation binder for immediate-release tablet cores. A 5–8% w/w aqueous binder solution is prepared in a jacketed vessel at 80–85°C with a propeller stirrer at 200–300 rpm for 45–60 min, then cooled to 25–30°C before introduction into the granulator bowl. The dry-binder level is 2–4% w/w of the total core mass; lower levels often produce inadequate tensile strength in high-dose, poorly compressible actives, while levels above 5% w/w can increase wet mass stickiness and extend disintegration beyond 15 min. Granulation proceeds in a 10 L high-shear granulator at impeller speed 300–500 rpm and chopper speed 1500–2500 rpm, with purified water added separately to a final wet mass density of 0.45–0.60 g/mL. The wet granules are dried in a fluid bed with inlet air at 60–70°C until product temperature reaches 35–40°C and loss on drying is 1.5–2.5% w/w. Milling through a 0.8–1.25 mm screen yields D50 granules of 150–250 µm, a range that provides sufficient flow without excessive fines segregation. Compression on a rotary press with main compression force 8–20 kN produces tablets with hardness 60–120 N and friability ≤0.8% according to USP <1216>. Disintegration under USP <701> in 0.1 M HCl is typically ≤15 min when the binder level is within the specified range and residual moisture is not above 2.5% w/w. The final oral solid dose form is a conventional immediate-release tablet with no modified-release claim. Batch-to-batch viscosity variation in PVA is a primary control parameter; a shift above 6.0 mPa·s at 4% can change granule size distribution and dissolution under USP <711> at 50 rpm paddle speed.

What Processing Limits Govern Aqueous PVA Film Coating on Perforated Drum Coaters?

Aqueous PVA film coating on perforated drum coaters fails in two directions: low bed temperature causes spray-dried polymer loss, while bed temperature above 45°C causes tablet tacking and surface roughness. The coating dispersion contains PVA at 6–8% w/w, PEG 400 at 15–25% w/w of PVA solids, talc at 25–35% w/w of PVA solids, and titanium dioxide at 10–20% w/w of PVA solids in purified water. The dispersion is sprayed through a 0.8–1.2 mm two-fluid nozzle at atomising air pressure 1.5–2.5 bar and spray rate 8–15 g/min onto a 24-inch perforated pan running at 6–12 rpm. Inlet air is controlled at 65–75°C, bed temperature at 38–45°C, and exhaust air flow at 100–200 CFM; the bed-temperature processing window of ±3°C around the formulation-specific target is the limiting parameter. At bed temperature below 36°C, evaporation efficiency is insufficient and the remaining water can cause tablet logo bridging and film cracking. At bed temperature above 45°C, the PVA film enters its tacky regime before complete coalescence, leading to tablet-to-tablet sticking and unacceptable surface roughness measured by profilometry. A coating weight gain of 2–4% w/w is applied for immediate-release moisture-barrier coatings; higher weight gains can extend disintegration beyond 30 min and alter dissolution under USP <711>. The dried film after conditioning at 23°C/50% RH for 48 h has a tensile strength of 20–40 MPa and elongation at break of 100–200% when tested according to ASTM D882-18. The coating process is terminated after the target weight gain is reached; coated tablets are then tray-dried at 40°C for 2–4 h to remove residual surface moisture before packaging.

Capsule Shell Dip-Moulding and Banding with PVA: Gelation Temperature, Pin Withdrawal Rate, and Residual Solvent Limits

For dip-moulded capsule shells, PVA solutions are prepared at 10–18% w/w and heated to 80–90°C under vacuum to remove entrapped air; the solution viscosity at 60°C is maintained at 300–800 mPa·s using a Brookfield viscometer per ASTM D2196-20. Stainless steel pin bars are preheated to 40–60°C, dipped into the solution, withdrawn at 5–15 mm/s, and rotated to form a uniform film. Gelation begins at the solution-air-pin interface as temperature drops in a cooling tunnel at 4–12°C for 10–30 min; the capsule body then moves to drying chambers at 30–40°C and 20–30% RH for 6–12 h. Residual methanol is controlled to ≤3,000 ppm according to ICH Q3C(R8) Class 2 limits and residual peroxide is limited to avoid oxidative degradation of oxygen-sensitive fill formulations. PVA capsule shells are used when gelatin crosslinking with aldehyde-containing fill is unacceptable, when low moisture content is required for hygroscopic actives, or when dietary restrictions require a non-animal polymer. The final empty capsule must pass disintegration under USP <701>, microbial limits under USP <61> and <62>, and dissolution testing of the filled product under USP <711>. Banding of filled capsules uses a 5–10% w/w PVA solution applied at 40–50°C; the band must form a continuous seal without wicking into the capsule body. Published data for specific PVA capsule shell formulations are limited, so pin speed, gelation temperature, and residual solvent removal must be revalidated for each grade and capsule size.

In a Wurster fluidised bed fitted with a 0.8 mm two-fluid nozzle, a 5–7% w/w aqueous PVA coating solution is applied to oral granules at 3–5% w/w weight gain for taste masking and moisture protection prior to sachet or dry syrup filling. The inlet air temperature is 55–65°C, product temperature is 32–38°C, atomising air pressure is 1.2–2.0 bar, and spray rate is 5–10 g/min. Plasticizer is limited to 10–20% w/w of PVA solids to prevent tacking during storage. The coated granules are sieved through 1.25–1.60 mm to remove agglomerates and then filled by weight. Dissolution of the final granule dose is ≥85% within 30 min under USP <711> paddle at 50 rpm in 0.1 M HCl.

When PVA Is Added as a Pore Former in Modified-Release Barrier Membranes, the Leaching Kinetics Control Lag-Time Variability

When a modified-release barrier membrane requires in-situ pore formation after ingestion, PVA is incorporated into ethylcellulose or cellulose acetate organic or aqueous dispersion at 2–10% w/w of total polymer solids; the PVA particle size D90 is controlled at ≤50 µm to ensure reproducible pore distribution. The membrane is applied in a Wurster coater at 8–15% w/w weight gain, with inlet air 50–60°C and product temperature 28–34°C for aqueous dispersions, or 25–30°C product temperature for solvent-based systems. After drying, the coated pellets are cured at 40–50°C for 2–4 h; curing temperature must remain below the glass transition of the barrier polymer to avoid premature pore collapse. The lag time, defined as the interval before 10% drug release, shifts from 30–90 min depending on PVA loading and particle size; higher PVA content shortens lag time and increases release rate, but content above 10% w/w can generate interconnected channels that reproduce immediate-release profiles. Dissolution is performed under USP <711> with sequential media at 100 rpm basket speed. The final product is an extended-release pellet filling in a hard capsule, with the PVA phase completely dissolved in aqueous media leaving no solid residue in the gastrointestinal tract. Published data for a specific PVA grade in osmotic membranes is limited; screening trials on a laboratory-scale Wurster coater are required to establish the pore-former grade, loading, and curing window before scale-up.

Terminally sterilised PVA solutions intended for ophthalmic use are prepared at 1.4% w/v in purified water and autoclaved at 121°C for 15 min; post-sterile viscosity is measured with a Brookfield viscometer at 20°C and must remain within 2–15 mPa·s for ophthalmic lubricant formulations. Because autoclaving can shift viscosity by 5–10% depending on grade, the release specification includes post-sterile viscosity rather than pre-sterile alone. For injectable processing aids and parenteral suspension stabilisation, the aqueous PVA solution is filtered through a 0.22 µm sterilising-grade filter; viscosity above 15 mPa·s reduces flux and can exceed filter capacity. Bacterial endotoxin is controlled to ≤0.25 EU/mL by LAL per USP <85>, particulate matter is tested under USP <788> for small-volume injectables, and sterility testing follows USP <71>. The limiting incompatibility is with high concentrations of borate or strongly alkaline buffers, which can crosslink or gel PVA and prevent sterile filtration. For ophthalmic multidose containers, preservative compatibility is assessed by preservative efficacy testing under USP <51> because PVA can adsorb benzalkonium chloride and reduce antimicrobial activity. Published data for specific injectable PVA configurations is limited, so terminal sterilisation validation must include viscosity, pH, endotoxin, and particulate results from three consecutive production-scale batches.